Literature DB >> 6110092

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

G B Klintmalm, S Iwatsuki, T E Starzl.   

Abstract

In six of twelve orthotopic liver recipients nephrotoxicity was noted after 13-22 days of treatment with 16.3 + or - 2.9 (SEM) mg/kg per day of cyclosporin A (CyA). With a decrease in the daily CyA dose to 9.2 + or - 2.3 (SEM) mg/kg kidney function returned to normal. No hepatic rejections occurred on this lowered CyA dose. In 4 out of 66 kidney recipients a switch from a CyA dose of 5.2 - 10.7 mg/kg daily to azathioprine was done 4 - 8 months after transplant because of unsatisfactory kidney function, suspected to be due to nephrotoxicity. In three patients, this resulted in an improved graft function. A fourth transplant was lost to an irreversible rejection 13 days later. Thus CyA is nephrotoxic but this toxicity is easily reversed, even after many months of treatment, and the ease with which this complication can be managed suggests that nephrotoxicity should not diminish the high expectations that transplant surgeons have for CyA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6110092      PMCID: PMC3032533          DOI: 10.1016/s0140-6736(81)91851-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Liver transplantation, 1980, with particular reference to cyclosporin-A.

Authors:  T E Starzl; S Iwatsuki; G Klintmalm; G P Schröter; R Weil; L J Koep; K A Porter
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

3.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

4.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

5.  Cyclosporin A for the treatment of graft-versus-host disease in man.

Authors:  R L Powles; A J Barrett; H Clink; H E Kay; J Sloane; T J McElwain
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

6.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07
  6 in total
  46 in total

1.  Factors in the Development of Liver Transplantation.

Authors:  T E Starzl; S Iwatsuki; B W Shaw; R D Gordon; C Esquivel; S Todo; I Kam; S Lynch
Journal:  Transplant Proc       Date:  1985-10       Impact factor: 1.066

Review 2.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.

Authors:  Wen-ying Shu; Jia-li Li; Xue-ding Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

5.  Liver transplantation in the ciclosporin era.

Authors:  T E Starzl; S Iwatsuki; B W Shaw; R D Gordon; C Esquivel
Journal:  Prog Allergy       Date:  1986

6.  Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Authors:  P Bertault-Pérès; D Maraninchi; Y Carcassonne; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.

Authors:  T E Starzl; T R Hakala; J T Rosenthal; S Iwatsuki; B W Shaw
Journal:  Surg Gynecol Obstet       Date:  1982-06

8.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

9.  Inhibition of contact sensitivity reactions to DNFB by topical cyclosporin application in the guinea-pig.

Authors:  R D Aldridge; A W Thomson; R Rankin; P H Whiting; C Cunningham; J G Simpson
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

10.  Renal function in rats treated with cyclosporin following unilateral nephrectomy.

Authors:  P H Whiting; J I Duncan; M P Gavin; S D Heys; J G Simpson; S K Asfar; A W Thomson
Journal:  Br J Exp Pathol       Date:  1985-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.